N-(2-bromophenyl)-5-(4-guanidinophenyl)isoxazole-3-carboxamide hydrochloride | 1612893-76-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-bromophenyl)-5-(4-guanidinophenyl)isoxazole-3-carboxamide hydrochloride
• 英文别名: N-(2-bromophenyl)-5-[4-(diaminomethylideneamino)phenyl]-1,2-oxazole-3-carboxamide;hydrochloride
• CAS: 1612893-76-1
• 化学式: C₁₇H₁₄BrN₅O₂*ClH
• 分子量: 436.695
• InChiKey: XRRXARWDWYHNSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.68
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  120
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-(4-guanidinophenyl)isoxazole-3-carboxylic acid hydrochloride 、 2-溴苯胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二甲基亚砜 为溶剂， 反应 48.0h， 以70%的产率得到N-(2-bromophenyl)-5-(4-guanidinophenyl)isoxazole-3-carboxamide hydrochloride
  参考文献：
  名称：

  Design and synthesis of phenylisoxazole derivatives as novel human acrosin inhibitors

  摘要：

  Human acrosin is an attractive target for the discovery of novel male contraceptives. Isoxazole derivative ISO-1, a small-molecule weak human acrosin inhibitor, was used as the starting point for lead optimization. After two rounds of structure-based inhibitor design, a highly potent inhibitor B6 (IC50 = 1.44 mu M) was successfully identified, which showed good selectivity over trypsin and represents one of the most active human acrosin inhibitors up to date. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.04.118

文献信息

• Design and synthesis of phenylisoxazole derivatives as novel human acrosin inhibitors
  作者：Juntao Zhao、Wei Tian、Jingjing Qi、Diya Lv、Yang Liu、Yan Jiang、Guoqiang Dong、Qianqian Chen、Youjun Zhou、Ju Zhu、Heling Wang、Chunquan Sheng、Jiaguo Lv

  DOI：10.1016/j.bmcl.2014.04.118

  日期：2014.7

  Human acrosin is an attractive target for the discovery of novel male contraceptives. Isoxazole derivative ISO-1, a small-molecule weak human acrosin inhibitor, was used as the starting point for lead optimization. After two rounds of structure-based inhibitor design, a highly potent inhibitor B6 (IC50 = 1.44 mu M) was successfully identified, which showed good selectivity over trypsin and represents one of the most active human acrosin inhibitors up to date. (C) 2014 Elsevier Ltd. All rights reserved.